Neoadjuvant chemotherapy with Cabazitaxel in high risk prostate cancer patients prior to radical prostatectomy Neoadjuvante Chemotherapie mit Cabazitaxel vor der radikalen Prostatektomie

Trial Profile

Neoadjuvant chemotherapy with Cabazitaxel in high risk prostate cancer patients prior to radical prostatectomy Neoadjuvante Chemotherapie mit Cabazitaxel vor der radikalen Prostatektomie

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Cabazitaxel (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms CLUBNET-CABAZ
  • Sponsors Sanofi
  • Most Recent Events

    • 12 Sep 2016 Status changed from suspended to discontinued as the investigator left the site
    • 15 Sep 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 12 Sep 2013 Planned end date changed from 12 Jun 2015 to 1 Aug 2018, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top